Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelly Hayward

Nurse Practitioner Springfield, MA Nurse Practitioner

NPI 1275186041 CMS profile 10955118

125 Liberty St Ste 204, Springfield, MA 01103

Open in the dashboard

General payments

$1,529

39 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Hayward of Springfield, MA is reported in the CMS Open Payments database as having received $1,529 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $234 9
2024 General $755 7
2023 General $149 6
2022 General $68 3
2021 General $323 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Hayward
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kelly Hayward were reported at $234. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kelly Hayward Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $323 $135 $40–$426 $132
2022 $68 $152 $48–$470 $149
2023 $149 $166 $54–$529 $160
2024 $755 $173 $55–$556 $164
2025 $234 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $673 4 payments
  2. SPR Therapeutics, Inc $349 13 payments
  3. Gilead Sciences, Inc. $216 9 payments
  4. AbbVie, Inc. $154 7 payments
  5. Alkermes, Inc. $37 2 payments
  6. Stryker Corporation $35 1 payment
  7. Relievant Medsystems, Inc. $27 1 payment
  8. Curonix LLC $20 1 payment
  9. Pacira Pharmaceuticals Incorporated $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,224 37 payments
  2. Travel and Lodging $290 1 payment
  3. Education $15 1 payment
Products named General payments · program years 2021–2025
  1. SPRINT PNS System $349 13 payments
  2. MAVYRET $154 7 payments
  3. VIVITROL $37 2 payments
  4. MILD DEVICE KIT $35 1 payment
  5. OPTABLATE $35 1 payment
  6. Intracept Pain $27 1 payment
  7. Intracept Pain $27 1 payment
  8. Intracept Pain $27 1 payment
  9. Intracept Pain $27 1 payment
  10. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $20 1 payment
  11. Other $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

710

Median for Nurse Practitioner: 389

Drug cost

$47,697

Median for Nurse Practitioner: $21,885

Branded share of claims

15.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 38 $35,433
Lidocaine Generic 46 $3,241
Oxycodone Hcl Generic 89 $1,414
Pregabalin Generic 33 $1,189
Tizanidine Hcl Generic 83 $1,039
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 35 $941
Gabapentin Generic 89 $916
Baclofen Generic 38 $761
Methocarbamol Generic 44 $570
Celecoxib Generic 23 $530

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$19,986

Medicare's payments for the services billed

Medicare patients

189

Average age 69

Services billed

409

119 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 63%
Depression 35%
Diabetes 31%
COPD 25%
Chronic kidney disease 19%
Ischemic heart disease 16%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record